Table 1.
Clinical outcomes of SEMS placement in patients with post-operative nonanastomotic strictures in the proximal small bowel
| Patient no./Age (y)/Sex | Most recent abdominal Op | Stricture | Prior FBD | Comorbidities | SEMS | Dysphagia score | Complications/ Stent malfunction |
Reintervention | SEMS dwell time (d) |
Recur-ree time (d) | FU time (d) | |||||
| Time post -Op (d) |
Location | Length (cm) | Type | Length (cm) | Diameter (mm) | Before SEMS |
After SEMS | |||||||||
| 1/69/M | TG with EJ | 1332 | Prox Jej | 5 | + | HTN, T2DM | FC | 8 | 16 | 3 | 2 | -/Tissue hyperplasia | Required FSR | 32 | 38 | 167 |
| 1/69/M | TG with EJ | 1500 | Prox Jej | 7 | + | HTN, T2DM | PC | 8 | 16 | 3 | 2 | -/- | - | 35 | 35 | 35a |
| 2/56/M | TG with EJ | 823 | Prox Jej | 4 | - | IPF | PC | 5 | 18 | 3 | 2 | -/Stent migration | Required FSR | 24 | 59 | 59b |
| 3/72/M | TG with EJ | 97 | Prox Jej | 6 | - | Lung CA | UNC | 10 | 20 | 4 | 2 | -/- | - | 576 | 576 | 576c |
| 4/55/F | TG with EJ | 167 | Prox Jej | 3 | - | - | FC | 7 | 16 | 3 | 2 | -/Stent migration | Required SSR | 18 | 1778 | 1778 |
| 5/63/M | TG with EJ | 21 | Prox Jej | 4 | - | HTN | PC | 8 | 18 | 4 | 2 | -/Stent migration | Required SSR | 79 | 1714 | 1714 |
| 6/68/M | TG with EJ | 2070 | Prox Jej | 4 | + | Prostate CA | FC | 8 | 16 | 3 | 2 | -/- | Elective FSR | 31 | 68 | 72 |
| 6/68/M | TG with EJ | 2142 | Prox Jej | 4 | + | Prostate CA | FC | 8 | 16 | 3 | 1 | -/- | Elective FSR | 30 | 670 | 675 |
| 6/70/M | TG with EJ | 2817 | Prox Jej | 7 | + | Prostate CA | FC | 11 | 16 | 3 | 1 | -/Tissue hyperplasia | Required FSR | 225 | 225 | 231 |
| 6/71/M | TG with EJ | 3048 | Prox Jej | 7 | + | Prostate CA | FC | 11 | 16 | 3 | 1 | -/Tissue hyperplasia | Required FSR | 193 | 193 | 246 |
| 7/57/M | TG with EJ | 188 | Prox Jej | 3 | + | - | PC | 6 | 18 | 3 | 2 | -/Tissue hyperplasia | Required FSR | 237 | 237 | 733 |
| 8/70/M | TG with EJ | 141 | Prox Jej | 9 | + | - | FC | 13 | 16 | 3 | 2 | -/Stent migration | Required FSR | 4 | 21 | 33 |
| 8/71/M | TG with EJ | 174 | Prox Jej | 6 | + | - | FC | 10 | 16 | 3 | 2 | -/Stent migration | Required FSR | 4 | 10 | 14 |
| 8/71/M | TG with EJ | 188 | Prox Jej | 6 | + | - | FC | 10 | 16 | 3 | 2 | -/Stent migration | Required FSR | 5 | 58 | 64 |
| 8/71/M | TG with EJ | 252 | Prox Jej | 9 | + | - | FC | 10 | 16 | 3 | 2 | -/- | Elective FSR | 33 | 42 | 48 |
| 8/71/M | TG with EJ | 300 | Prox Jej | 9 | + | - | FC | 10 | 16 | 3 | 1 | -/- | Elective FSR | 369 | 513 | 520 |
| 8/72/M | TG with EJ | 820 | Prox Jej | 6 | + | - | FC | 8 | 16 | 3 | 2 | -/- | - | 20 | 20 | 20 |
CA, cancer; EJ, esophagojejunostomy; FBD, fluoroscopic balloon dilation; FC = fully-covered;FSP, fluoroscopic stent placement; FSR, fluoroscopic stent removal; FU, follow up; HTN, hypertension; IPF, interstitial pulmonary fibrosis; Jej, jejunum; OP, operation; PC, partially-covered; Prox, proximal; Recur, recurrence; SEMS, self-expandable metallic stent; SSR, surgical stent removal; T2DM, Type two diabetes mellitus; TG, total gastrectomy; UNC, uncovered.
a
Patient died due to myocardial infarction.
b
Patient died due to pneumonia.
c
Patient died due to recurrent lung cancer.